Cefaly Technology
Cefaly Technology develops FDA-cleared external trigeminal nerve stimulation (eTNS) devices for migraine treatment and prevention, selling direct-to-consumer and through the U.S. Veterans Health Administration, with a companion app and recurring electrode consumables.
- Company typePrivate
- Founded2004
- HeadquartersSeraing, Belgium
- Headcount11–50
- GTM typeB2C
- OfferingHardware or Manufacturing
What Cefaly Technology does
Cefaly Technology is a Belgium-headquartered medical device company that develops and sells FDA-cleared external trigeminal nerve stimulation (eTNS) devices for the acute treatment and preventive management of migraine. Founded in 2004 and headquartered in Liège with a U.S. subsidiary in Darien, Connecticut (established 2014), the company sells a portfolio of three device models — Cefaly Connected, Cefaly Enhanced, and Cefaly DUAL — that deliver two treatment modes: a 60-minute Acute program for use at migraine onset and a 20-minute daily Prevent program for frequency reduction. The core technology uses a forehead-placed electrode secured via a proprietary magnetic attachment system that delivers precise electrical stimulation to the trigeminal nerve, with the Cefaly Connected variant adding Bluetooth connectivity that pairs with the CeCe companion mobile app for real-time treatment tracking, symptom logging, and integration with health platforms (Apple Health, Google Health, Garmin, Fitbit, Oura) through the Terra SDK.
The company monetizes primarily through one-time hardware sales of its devices via a direct-to-consumer e-commerce channel (cefaly.com and Shopify storefront), supplemented by recurring revenue from replacement electrodes sold through a subscription auto-delivery program. Both devices and electrodes are HSA/FSA eligible, and the company offers a 90-day money-back guarantee, financing through Affirm and PayPal Credit, and free one-on-one coaching to reduce purchase friction. Revenue is not publicly disclosed. The company holds a first-mover FDA regulatory position — first FDA-cleared device for migraine prevention (2014), first FDA clearance for acute treatment (2017), and OTC approval (2020) — and has accumulated outcomes data from over 300,000 users supported by ACME, TEAM, and PREMICE clinical studies.
Cefaly sells primarily to individual migraine sufferers via D2C, with the U.S. Veterans Health Administration serving as a major institutional channel — Cefaly Connected became the #1 prescribed neuromodulation device among VA providers in 2024, accounting for 53% of 21,593 prescriptions. The company also pursues clinician adoption through a provider certification program, distributes multi-language content (English, French, Spanish) across an active blog and social media presence, and serves customers in the U.S., Canada, and Europe. Leadership comprises CEO Andy Page, CTO John Bradbury, CFO Vincent Denis, and Medical Affairs Advisor Dr. Michael A. L. Johnson, with co-founders Pierre Rigaux and Pierre-Yves Muller historically associated with the company. Cefaly operates as a privately-held entity with no disclosed parent company, institutional investor, or recent funding round.
Cefaly Technology firmographics
Firmographics- Name
- Cefaly Technology
- Legal name
- CEFALY Technology SRL
- Website
- https://cefaly.com
- Company type
- Private
- Founded year
- 2004
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Cefaly Technology develops FDA-cleared external trigeminal nerve stimulation (eTNS) devices for migraine treatment and prevention, selling direct-to-consumer and through the U.S. Veterans Health Administration, with a companion app and recurring electrode consumables.
- Ownership category
- akta.pro rank
Cefaly Technology industry classification
Industry- Product category
- Neuromodulation Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)
Keywords
Where Cefaly Technology is headquartered
LocationHeadquarters
- HQ city
- Seraing
- HQ country
- Belgium
- HQ region
- Europe
Offices2 records
Markets served
Cefaly Technology business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Medical Device Sales: One-time sales of Cefaly neuromodulation devices (Cefaly Connected, Cefaly Enhanced) directly to consumers through e-commerce website. Devices are FDA-cleared for migraine treatment and prevention.
- Electrode Consumables: Recurring revenue from sale of replacement electrodes (sold in packs of 3). Electrodes are reusable and can be replenished through auto-delivery subscription with free shipping and 5% discount.
- HSA/FSA Eligible Products: Both devices and electrodes qualify as HSA/FSA eligible expenses, enabling customers to use pre-tax health account funds for purchases, expanding addressable market.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | Cefaly Connected Device |
| Subscription | Monthly | Electrode Subscription (Auto-delivery) |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels8 records
Cefaly Technology product offering
Product offeringCore offering
Cefaly Technology designs, manufactures, and sells FDA-cleared external trigeminal nerve stimulation (eTNS) devices for the acute treatment and prevention of migraine. Its product line includes the Cefaly Connected, Cefaly Enhanced, and Cefaly DUAL devices, supported by a Bluetooth-paired companion app (CeCe), reusable electrode consumables, and free one-on-one coaching services. The company sells primarily direct-to-consumer through its own e-commerce website and the Shopify storefront, with additional institutional distribution through the U.S. Veterans Health Administration.
Product overview
CEFALY Technology offers a family of FDA-cleared external trigeminal nerve stimulation (eTNS) neuromodulation devices for migraine treatment and prevention. The product portfolio consists of three device models (CEFALY Connected, CEFALY Enhanced, and CEFALY DUAL) delivering two treatment modes: Acute (60-minute sessions for migraine relief) and Prevent (20-minute daily sessions for migraine prevention). CEFALY Connected integrates with the CEFALY Migraine Relief app (CeCe) via Bluetooth for real-time treatment monitoring, symptom tracking, and health data integration from wearables. The ecosystem is supported by consumable electrodes (standard and hypoallergenic), a free one-on-one coaching service, and a subscription program for electrode auto-delivery.
Differentiator
Problem solved
Functional benefit
Brands
- Cefaly Connected: The primary connected neuromodulation device that pairs with the Cefaly app for real-time treatment tracking and monitoring.
- Cefaly Enhanced
- Cefaly DUAL
- CeCe App
Products and services
- Cefaly Connected Primary FDA-cleared eTNS neuromodulation device that stimulates the trigeminal nerve via a forehead electrode to treat and prevent migraines; features Bluetooth connectivity for app integration and real-time treatment monitoring. Sold direct-to-consumer with a 90-day money-back guarantee.
- Cefaly Enhanced FDA-cleared neuromodulation device for migraine treatment and prevention using external trigeminal nerve stimulation, featuring purple (Prevent) and aqua (Acute) LED indicators to differentiate treatment modes.
- Cefaly DUAL Earlier generation neuromodulation device with dual treatment modes (Prevent and Acute) for migraine relief, featuring green LED indicator lights.
- Cefaly Migraine Relief App (CeCe) Free companion mobile application for Cefaly Connected that enables Bluetooth pairing, real-time treatment selection, adjustment and monitoring, migraine tracking, health data integration from wearables, and personalized migraine reports.
- Cefaly Electrodes Adhesive electrode accessories for use with Cefaly devices, available in standard and hypoallergenic variants (for users with acrylate allergy); sold in packs of 3 with optional auto-delivery subscription.
- Cefaly Coach Free one-on-one coaching service providing Cefaly users with assistance on device usage, treatment mode selection, intensity adjustment, troubleshooting, and app usage optimization.
Quantifiable outcome
- 79% of patients saw significant reduction in headache pain after 1 hour of Acute treatment
- +3 more outcomes
Companies that use Cefaly Technology
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
Cefaly Technology technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration9 records
Feature6 records
Cefaly Technology partnerships and signals
Strategic signalScale indicators6 records
Recent moves7 records
Expansion highlights5 records
Cefaly Technology competitors and assessment
Company assessmentDirect peers
- electroCore (gammaCore): electroCore makes gammaCore, a non-invasive vagus nerve stimulation (nVNS) device FDA-cleared for migraine and cluster headache. It is the closest direct competitor to Cefaly — both are prescription/OTC neuromodulation devices targeting the same headache patient population with similar clinical and DTC strategies.
- Theranica (Nerivio): Theranica's Nerivio is a wearable remote electrical neuromodulation (REN) device for acute and preventive migraine treatment, controlled via smartphone app. It directly competes with Cefaly Connected in the connected, app-paired neuromodulation category for migraine.
- eNeura (sTMS mini): eNeura manufactures the sTMS mini, a single-pulse transcranial magnetic stimulation device FDA-cleared for acute and preventive treatment of migraine. It competes with Cefaly in the neuromodulation-for-migraine category with a different stimulation modality (magnetic vs. electrical).
Broad incumbents
- Saluda Medical: Saluda Medical develops implantable spinal cord and dorsal root ganglion stimulation systems for chronic pain and other neurological conditions. While implantable rather than external, it is a comparable neurostimulation medtech player addressing chronic neurological conditions with similar regulatory and clinical evidence requirements.
- Axonics Modulation Technologies: Axonics manufactures implantable sacral and pudendal neuromodulation devices for bladder/bowel dysfunction. As a public neuromodulation pure-play, it provides a comparable public-market benchmark for neurostimulation device economics and adoption curves.
- Inspire Medical Systems: Inspire Medical Systems produces an implantable hypoglossal nerve stimulation device for obstructive sleep apnea. It is a successful public neurostimulation medtech company and serves as a benchmark for the commercial trajectory of a single-indication neurostim device.
- NeuroPace: NeuroPace makes the RNS System, an implanted responsive neurostimulator for refractory epilepsy. It is an adjacent neurostimulation medtech company addressing chronic neurological conditions with similar regulatory, evidence, and clinician-adoption challenges as Cefaly.
Emerging players
- Cala Health: Cala Health develops wearable transcutaneous afferent patterned stimulation (TAPS) therapy for essential tremor and other neurological conditions. It is an emerging wearable neurostim company targeting chronic neurological conditions with a similar consumer/clinical hybrid go-to-market model.
- Helius Medical Technologies: Helius Medical Technologies develops portable neuromodulation devices (PoNS) for neurological symptoms from traumatic brain injury and multiple sclerosis. It is an emerging non-invasive neurostim company addressing chronic neurological conditions via a prescription device model.
Others
- AbbVie (Botox) / Pfizer / Lilly (CGRP inhibitors): Major pharmaceutical manufacturers of migraine therapies (Botox, CGRP inhibitors like Aimovig, Emgality, and Reyvow) compete for the same neurologist prescriptions and patient population. They represent the principal non-device therapeutic alternatives Cefaly must differentiate against.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Cefaly Technology social profiles
Digital presenceCefaly Technology compliance and trust
Trust signalCompliance3 records
Cefaly Technology financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cefaly Technology leadership team
Management profileNumber of profiles
Profiles7 records
Cefaly Technology funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cefaly Technology M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cefaly Technology
What does Cefaly Technology do?
Cefaly Technology designs, manufactures, and sells FDA-cleared external trigeminal nerve stimulation (eTNS) devices for the acute treatment and prevention of migraine. Its product line includes the Cefaly Connected, Cefaly Enhanced, and Cefaly DUAL devices, supported by a Bluetooth-paired companion app (CeCe), reusable electrode consumables, and free one-on-one coaching services. The company sells primarily direct-to-consumer through its own e-commerce website and the Shopify storefront, with additional institutional distribution through the U.S. Veterans Health Administration.
Is Cefaly Technology a public or private company?
Cefaly Technology is a private company. It is classified as private equity controlled and is currently operating.
When was Cefaly Technology founded?
Cefaly Technology was founded in 2004. It employs 11 to 50 people.
Where is Cefaly Technology based?
Cefaly Technology is headquartered in Seraing, Belgium, in the Europe region.
How does Cefaly Technology make money?
Three revenue lines are on record. Medical Device Sales are the primary driver. The others are electrode Consumables and HSA/FSA Eligible Products.
Who are Cefaly Technology's main competitors?
Direct peers on record are electroCore (gammaCore), Theranica (Nerivio) and eNeura (sTMS mini). Broad incumbents are Saluda Medical, Axonics Modulation Technologies, Inspire Medical Systems and NeuroPace. Emerging players are Cala Health and Helius Medical Technologies. AbbVie (Botox) / Pfizer / Lilly (CGRP inhibitors) is listed as an others.
Does Cefaly Technology have an API?
No public API is recorded for Cefaly Technology.
What industry is Cefaly Technology in?
Cefaly Technology's product category is Neuromodulation Medical Devices. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS). Its NAICS code is 334510 and its SIC code is 3845.